A new approach to study semi-coordination using two 2-methyl-5-nitroimidazole copper(ii) complexes of biological interest as a model system

Two novel copper(ii) complexes [Cu(2mni)2(H2O)2](NO3)2·2H2O (1) and [Cu(2mni)2(NO3)2] (2), where 2mni is 2-methyl-5-nitroimidazole, were prepared and characterized in the solid state using single-crystal and powder X-ray diffraction analyses, EPR, electronic and vibrational spectroscopies (FTIR and Raman), and thermogravimetric methods. Both products present an elongated distorted octahedral geometry with axial Cu-O bond lengths of 2.606(14) and 2.593(15) Å, indicating semi-coordination. Density functional theory (DFT) calculations at the B3LYP/LANL2DZ theory level were used to study the electronic properties of 1 and 2. The Independent Gradient Model (IGM) was employed to determine the Intrinsic Bond Strength Index (IBSI) of the semi-coordination and to plot δg isosurfaces for the electronic sharing between the metal center and ligands. A moderate to weak antibacterial activity against Escherichia coli cultures was found for 1 with a 50% growth inhibition (GI50) value of 0.25 mmol L-1. To the best of our knowledge, this is the first time that the semi-coordination analysis using IGM was carried out for a copper(ii) complex with axial elongation, finding a good correlation between the bond length and the IBSI, and the study was extended for a series of analogous complexes described in the literature.

In Vitro, Oral Acute, and Repeated 28-Day Oral Dose Toxicity of a Mixed-Valence Polyoxovanadate Cluster

Polyoxovanadates (POV) are a subgroup of polyoxometalates (POM), which are nanosized clusters with reported biological activities. This manuscript describes the first toxicity evaluation of a mixed-valence polyoxovanadate, pentadecavanadate, (Me4N)6[V15O36Cl], abbreviated as V15. Cytotoxicity experiments using peripheral blood mononuclear cells (PBMC), larvae of Artemia salina Leach, and in vivo oral acute and repeated 28-day doses in mice was carried out. The LC50 values in PBMC cells and A. salina were 17.5 ± 5.8 μmol L-1, and 17.9 µg L-1, respectively, which indicates high cytotoxic activity. The toxicity in mice was not observed upon acute exposure in a single dose, however, the V15 repeated 28-day oral administration demonstrated high toxicity using 25 mg/kg, 50 mg/kg and, 300 mg/kg doses. The biochemical and hematological analyses during the 28-day administration of V15 showed significant alteration of the metabolic parameters related to the kidney and liver, suggesting moderate toxicity. The V15 toxicity was attributed to the oxidative stress and lipid peroxidation, once thiobarbituric acid (TBAR) levels significantly increased in both males and females treated with high doses of the POV and also in males treated with a lower dose of the POV. This is the first study reporting a treatment-related mortality in animals acutely administrated with a mixed-valence POV, contrasting with the well-known, less toxic decavanadate. These results document the toxicity of this mixed-valence POV, which may not be suitable for biomedical applications.

The antihyperglycemic and hypolipidemic activities of a sulfur-oxidovanadium(IV) complex

This study describes the synthesis, characterization, and biological activity of a new class of antidiabetic oxidovanadium(IV)-complexes with S₂O₂ coordination mode. The target complex 3,6-dithio-1,8-octanediolatooxidovanadium(IV), abbreviated as ([V^IVO(octd)]), where octd = 3,6-dithio-1,8-octanediol, is formed from the reaction between the 3,6-dithio-1,8-octanediol and vanadyl sulfate (V^IVOSO₄). The effects of treatment with ([V^IVO(octd)] on blood glucose, lipidic profile, body weight, food intake, water intake, urinary volume, glycogen levels, and biomarkers for liver toxicity were investigated using a streptozotocin (STZ)-induced diabetic Wistar rats model. The results have shown that the [V^IVO(octd)] complex caused a significant decrease in blood glucose (247.6 ± 19.3 mg/dL vs 430.1 ± 37.6 mg/dL diabetic group, p < 0.05), triglycerides (TG, 50%) and very low-density cholesterol (VLDL-C, 50%) levels in STZ-diabetic rats after 3 weeks of treatment. The [V^IVO(octd)] has shown antihyperglycemic activity in diabetic rats as well as a reduction in elevated lipid levels. Time-dependent studies using EPR and ⁵¹V NMR spectroscopy of [V^IVO(octd)] were done in aqueous solutions to determine the complex stability and species present in the oral gavage solution used for complex administration. The spectroscopic studies have shown that the antidiabetic/hypolipidemic activity could be attributed to [V^IVO(octd)], vanadium species resulting from redox processes, the hydrolysis of [V^IVO(octd)] and its decomposition products, or some combination of these factors. In summary, the oxidovanadium(IV) complex containing the S₂O₂ donor ligand has desirable antidiabetic properties eliminating the symptoms of Diabetes mellitus and its comorbidities.

Polyoxovanadates as new P-glycoprotein inhibitors: insights into the mechanism of inhibition

A promising strategy to overcome multidrug resistance is the use of inhibitors of ABC drug transporters. For this reason, we evaluated the polyoxovanadates (POVs) [V₁₀ O₂₈ ]^6- (V₁₀ ), [H₆ V₁₄ O₃₈ (PO₄ )]^5- (V₁₄ ), [V₁₅ O₃₆ Cl]^6- (V₁₅ ) and [V₁₈ O₄₂ I]^7- (V₁₈ ) as inhibitors of three major multidrug resistance-linked ABC transporters: P-glycoprotein (P-gp), ABCG2 and MRP1. All of the POVs selectively inhibited P-gp. V₁₀ and V₁₈ were the two most promising compounds, with IC₅₀ values of transport inhibition of 25.4 and 22.7 µm, respectively. Both compounds inhibited P-gp ATPase activity, with the same IC₅₀ value of 1.26 µm. V₁₀ and V₁₈ triggered different conformational changes in the P-gp protein with time-dependent inhibition, which was confirmed using the synthesized salt of V₁₀ with rhodamine B, RhoB-V₁₀ . The hydrophilic nature of POVs supports the hypothesis that these compounds target an unusual ligand-binding site, opening new possibilities in the development of potent modulators of ABC transporters.

Stability in solution and chemoprotection by octadecavanadates(IV/V) in E. coli cultures

Two mixed-valence octadecavanadates, (NH₄)₂(Me₄N)₅[V^IV₁₂V^V₆O₄₂I]·Me₄NI·5H₂O (V₁₈I) and [{K₆(OH₂)₁₂V^IV₁₁V^V₇O₄₁(PO₄)·4H₂O}_n] (V₁₈P), were synthesized and characterized by single-crystal X-ray diffraction analysis and FTIR, Raman, ⁵¹V NMR, EPR and UV/Vis/NIR spectroscopies. The chemoprotective activity of V₁₈I and V₁₈P towards the alkylating agent diethyl sulfate was assessed in E. coli cultures. The complex V₁₈I was nontoxic in concentrations up to 5.0 mmol L^-1, while V₁₈P presented moderate toxicity in the concentration range 0.10 - 10 mmol L^-1. Conversely, a ca. 35% enhancement in culture growth as compared to cells treated only with diethyl sulfate was observed upon addition of V₁₈I (0.10 to 2.5 mmol L^-1), while the combination of diethyl sulfate with V₁₈P increased the cytotoxicity presented by diethyl sulfate alone. ⁵¹V NMR and EPR speciation studies showed that V₁₈I is stable in solution, while V₁₈P suffers partial breakage to give low nuclearity oxidometalates of vanadium(V) and (IV). According to the results, the chemoprotective effect depends strongly on the direct reactivity of the polyoxidovanadates (POV) towards the alkylating agent. The reaction of diethyl sulfate with V₁₈I apparently produces a new, rearranged POV instead of poorly-reactive breakage products, while V₁₈P shows the formation and subsequent consumption of low-nuclearity species. The correlation of this chemistry with that of other mixed-valence polyoxidovanadates, [H₆V^IV₂V^V₁₂O₃₈PO₄]^5- (V₁₄) and [V^IV₈V^V₇O₃₆Cl]^6- (V₁₅), suggests a relationship between stability in solution and chemoprotective performance.

PtIV- or MoVI-substituted decavanadates inhibit the growth of Mycobacterium smegmatis

Inhibitory effects of two monosubstituted decavanadates by Pt^IV in monoplatino(IV)nonavanadate(V) ([H₂Pt^IVV₉O₂₈]^5-, V₉Pt), and by Mo^IV in monomolybdo(VI)nonavanadate(V) ([Mo^VIV₉O₂₈]^5-,V₉Mo) were investigated against the growth of Mycobacterium smegmatis with the EC₅₀ values of 0.0048 mM and 0.015 mM, respectively. These compare to the reported inhibitory value for decavanadate ([V₁₀O₂₈]^6-/[HV₁₀O₂₈]^5-, V₁₀) on Mycobacterium smegmatis (EC₅₀ = 0.0037 mM). Time-dependent ⁵¹V NMR spectroscopic studies were carried out for all three polyanions in aqueous solution, biological medium (7H9), heated and non-heated supernatant to evaluate their stability in their respective media, monitor their hydrolysis to form various oxovanadates over time and calculate the EC₅₀ values. These studies allow us to calculate adjusted and maximum EC₅₀ for the polyoxovanadate (POV) present in solution at the beginning of the study when there is most intact anion in the media and thus the EC₅₀ values represent the initial effects of the POVs. The results have shown that V₁₀ is 1.3 times more potent than V₉Pt and 4 times more potent than V₉Mo, indicating that the inhibitory effects of monosubstituted polyanions are related to the V₁₀ structure. We attributed the minor differences in the growth inhibitory effects to the differences in charges (5- vs 6-) of V₉Pt and V₉Mo compared to V₁₀ and/or the differences in the chemical composition. We concluded that the potency of the growth inhibition by V₁₀ is mainly due to the chemical properties of the vanadium and the decametalate's unique structure even though the presence of the Mycobacterium smegmatis facilitate hydrolysis of the anions. SYNOPSIS: Two decavanadate derivatives, monoplatino(IV)nonavanadate(V) ([H₂Pt^IVV₉O₂₈]^5-), monomolybdo(VI)nonavanadate(V) ([Mo^VIV₉O₂₈]^5-) and decavanadate are more potent growth inhibitors of Mycobacterium smegmatis than monomeric vanadate. The spectroscopic characterization carried out in the growth medium led to the conclusion that both the decavanadate structure and its properties are important for its growth effects.

Vanadium(IV)-diamine complex with hypoglycemic activity and a reduction in testicular atrophy

The insulin enhancing activity, histological analysis and, testicular degeneration by a V^IVO-complex containing the 2,2'-(ethane-1,2-diylbis(azanediyl))diethanolate ligand, VO^IV(C₆H₁₄N₂O₂-κ²N,κ²O), abbreviated V^IVO(BHED), were investigated in diabetic male Wistar rats. The complex was administered by oral gavage of freshly prepared solutions of vanadium complex. Biological studies demonstrated that the vanadium complex normalized the elevated glucose levels in male Wistar rats with streptozotocin-induced diabetes and these compounds also avoided common responses in diabetic animals such as weight loss and reduction in the size of the epididymis, prostate, testis and seminal gland. The ⁵¹V NMR and EPR studies showed the formation of V^IVO(BHED) and the oxidation product [V^VO₂BHED]^- with two possible decomposition pathways. In summary, these studies demonstrate that the V^IVO(BHED) complex or its decomposition products show similar effects as insulin in decreasing elevated blood glucose levels.

Polyoxometalates function as indirect activators of a G protein-coupled receptor

A series of multivalent polyoxovanadates were found to activate signaling of a G protein coupled receptor, the luteinizing hormone receptor.

Chemoprotective activity of mixed valence polyoxovanadates against diethylsulphate in E. coli cultures: insights from solution speciation studies

Cell survival after treatment with dimethylsulphate in the presence of polyoxovanadates.